Interestingly, a significant level of EZH2 protein and EZH2–chromatin association on the day of treatment initiation could also be seen as an indication of a drug-independent mechanism of lymphocytosis commonly seen in CLL. This evidence concerns the gene EZH2 and B-cell chronic lymphocytic leukemia.